3-fluoro-4-nitrostyrene | 197777-90-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-fluoro-4-nitrostyrene
• 英文别名: 4-vinyl-2-fluoronitrobenzene；2-fluoro-1-nitro-4-vinyl-benzene；4-ethenyl-2-fluoro-1-nitrobenzene
• CAS: 197777-90-5
• 化学式: C₈H₆FNO₂
• 分子量: 167.14
• InChiKey: OKNXGWILKMLMGV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  45.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-fluoro-4-nitrostyrene 在 咪唑 、 盐酸 、 四氧化锇 、 Hydroquinone 1,4-phthalazinediyl diether 、 potassium carbonate 、 三苯基膦 、 potassium hexacyanoferrate(III) 、 偶氮二甲酸二乙酯 作用下， 以 四氢呋喃 、 甲醇 、 二氯甲烷 、 水 、 叔丁醇 为溶剂， 反应 16.0h， 生成 2-[(R)-1-(3-Fluoro-4-nitro-phenyl)-2-hydroxy-ethyl]-isoindole-1,3-dione
  参考文献：
  名称：

  SNAr macrocyclisation: A new approach towards the synthesis of D-O-E- segment of vancomycin

  摘要：

  DOI：

  10.1016/s0040-4039(97)01749-8
• 作为产物：
  描述：

  3-氟-4-硝基甲苯 在 N-溴代丁二酰亚胺(NBS) 、 偶氮二异丁腈 、 sodium carbonate 作用下， 以 四氯化碳 、 氯仿 、 水 、 苯 为溶剂， 反应 35.0h， 生成 3-fluoro-4-nitrostyrene
  参考文献：
  名称：

  SNAr macrocyclisation: A new approach towards the synthesis of D-O-E- segment of vancomycin

  摘要：

  DOI：

  10.1016/s0040-4039(97)01749-8

文献信息

• [EN] HETEROCYCLIC COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR<br/>[FR] COMPOSES HETEROCYCLIQUES CONVENANT POUR TRAITER DES TROUBLES SENSIBLES A UNE MODULATION DU RECEPTEUR D3 DE LA DOPAMINE
  申请人：ABBOTT GMBH & CO KG

  公开号：WO2006040182A1

  公开（公告）日：2006-04-20

  The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH2 or CHR3; R1 is H, C,-C6-alkyl, C,-C6-alkyl substituted by C3-C6-cycloalkyl, Cl-C6-hydroxyalkyl, fluorinated C,-C6-alkyl, C3-C6-cycloalkyl, fluorinated C3-C6-cycloalkyl, C3-C6­ alkenyl, fluorinated C3-C6-alkenyl, formyl, acetyl or propionyl; R2, R3 and R4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one ore more substituents selected from halogen, methyl, methoxy and CF3; E is NR5 or CH2, wherein R5 is H or C1 -C3-alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6- ­membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR8, where R8 is H, C1-C4-alkyl, fluorinated C1-C4-alkyl, C1-C4­alkylcarbonyl or fluorinated C1-C4-alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents Ra, wherein the variable Ra has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  该发明涉及以下式(I)的化合物，其中n为0、1或2；G为CH2或CHR3；R1为H、C1-C6烷基、被C3-C6环烷基取代的C1-C6烷基、Cl-C6羟基烷基、氟化的C1-C6烷基、C3-C6环烷基、氟化的C3-C6环烷基、C3-C6烯基、氟化的C3-C6烯基、甲酰基、乙酰基或丙酰基；R2、R3和R4独立地为H、甲基、氟甲基、二氟甲基或三氟甲基；A为苯基、吡啶基、嘧啶基、吡嗪基、吡啶嗪基或噻吩基，可以被卤素、甲基、甲氧基和CF3等一个或多个取代基取代；E为NR5或CH2，其中R5为H或C1-C3烷基；Ar为从苯基、含有1、2或3个异原子N、O和S的5-或6-元杂环芳基、以及与饱和或不饱和的5-或6-元碳环或杂环融合的苯基环组成的环状基，其中杂环环包含1、2或3个异原子N、O和S和/或1、2或3个异原子含氮基团，每个基团独立地选择自NR8，其中R8为H、C1-C4烷基、氟化的C1-C4烷基、C1-C4烷基酰基或氟化的C1-C4烷基酰基，环状基Ar可以携带1、2或3个取代基Ra，其中变量Ra具有权利要求和描述中给出的含义；以及其生理上可耐受的酸盐。该发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易受多巴胺D3受体配体治疗的医疗紊乱的药物组合物。
• Novel pyrazinone derivatives
  申请人：——

  公开号：US20030203907A1

  公开（公告）日：2003-10-30

  The present invention relates to a compound of the general formula (I): 1 [Ar 1 is aryl fused to the adjacent pyrazinone ring at the 5th and 6th positions, etc., X is CO, etc., Y is CH, etc., Z is CH, etc., V is CH, etc., W n is —(CH 2 ) n — (n is zero to four), R 1 is H or optionally substituted lower alkyl, etc., R 2 is H, etc., R 3 and R 4 are the same or different and are each H, etc., R 5 and R 6 are the same or different and are each H, hydroxy, etc.] or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition, an inhibitor of Cdk4 and/or Cdk6 or an anti-cancer agent, containing the same as an active ingredient; and a process for preparing them.

  本发明涉及一种通式(I)的化合物：1[Ar1是芳基，与相邻的吡唑酮环在第5和第6位置融合，等等，X是CO，等等，Y是CH，等等，Z是CH，等等，V是CH，等等，W是-(CH2)n-（n为零至四），R1是H或选择性取代的较低烷基，等等，R2是H，等等，R3和R4相同或不同，分别为H，等等，R5和R6相同或不同，分别为H，羟基，等等]或其药学上可接受的盐或酯；一种含有该化合物作为活性成分的制药组合物，Cdk4和/或Cdk6的抑制剂或抗癌剂；以及其制备方法。
• First and Second Generation Total Synthesis of the Teicoplanin Aglycon
  作者：Dale L. Boger、Seong Heon Kim、Yoshiki Mori、Jian-Hui Weng、Olivier Rogel、Steven L. Castle、J. Jeffrey McAtee

  DOI：10.1021/ja003835i

  日期：2001.3.1

  Full details of studies leading to the total synthesis of the teicoplanin aglycon are provided. Key elements of the first generation approach (26 steps from constituent amino acids, 1% overall) include the coupling of an EFG tripeptide precursor to the common vancomycin/teicoplanin ABCD ring system and sequential DE macrocyclization of the 16-membered ring with formation of the diaryl ether via a phenoxide

  提供了导致替考拉宁苷元全合成的研究的全部细节。第一代方法的关键要素（来自组成氨基酸的 26 个步骤，总体为 1%）包括将 EFG 三肽前体偶联到常见的万古霉素/替考拉宁 ABCD 环系统和 16 元环的顺序 DE 大环化，形成二芳基醚通过邻氟硝基芳族化合物（80%，3:1 阻转异构体非对映选择）的酚盐亲核芳族取代，然后通过大环内酰胺化（66%）进行 14 元 FG 环闭合。随后的研究提供了更短、更会聚和高度非对映选择性的第二代全合成（22 步，总体 2%）。这是通过改变闭环的顺序来实现的，这样 FG 大环内酰胺化 (95%) 先于 EFG 三肽偶联到 ABCD 环系统和随后的 DE 环闭合。值得注意的是，通过在底物 57 上形成二芳基醚的 DE 大环化，后者是包含完整 FG 环系统的后一种方法中的关键中间体，发生特殊的非对映选择以形成天然阻转异构体 (>10:1, 76%)，没有问题 C(2
• Heterocyclic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor
  申请人：Drescher Karla

  公开号：US20080045493A1

  公开（公告）日：2008-02-21

  The invention relates to compounds of the formula (I) wherein n is 0, 1 or 2; G is CH 2 or CHR 3 ; R 1 is H, C 1 -C 6 -alkyl, C 1 -C 6 -alkyl substituted by C 3 -C 6 -cycloalkyl, C 1 -C 6 -hydroxyalkyl, fluorinated C 1 -C 6 -alkyl, C 3 -C 6 -cycloalkyl, fluorinated C 3 -C 6 -cycloalkyl, C 3 -C 6 -alkenyl, fluorinated C 3 -C 6 -alkenyl, formyl, acetyl or propionyl; R 2 , R 3 and R 4 are, independently of each other, H, methyl, fluoromethyl, difluoromethyl, or trifluoromethyl; A is phenylene, pyridylene, pyrimidylene, pyrazinylene, pyridazinylene or thiophenylene, which can be substituted by one or more substituents selected from halogen, methyl, methoxy and CF 3 ; E is NR 5 or CH 2 , wherein R 5 is H or C 1 -C 3 -alkyl; Ar is a cyclic radical selected from the group consisting of phenyl, a 5- or 6-membered heteroaromatic radical comprising as ring members 1, 2 or 3 heteroatoms selected from N, O and S and a phenyl ring fused to a saturated or unsaturated 5- or 6-membered carbocyclic or heterocyclic ring, where the heterocyclic ring comprises as ring members 1, 2 or 3 heteroatoms selected from N, O and S and/or 1, 2 or 3 heteroatom-containing groups each independently selected from NR 8 , where R 8 is H, C 1 -C 4 -alkyl, fluorinated C 1 -C 4 -alkyl, C 1 -C 4 -alkylcarbonyl or fluorinated C 1 -C 4 -alkylcarbonyl, and where the cyclic radical Ar may carry 1, 2 or 3 substituents R a , wherein the variable R a has the meanings given in the claims and in the description; and physiologically tolerated acid addition salts thereof. The invention also relates to the use of a compound of the formula I or a pharmaceutically acceptable salt thereof for preparing a pharmaceutical composition for the treatment of a medical disorder susceptible to treatment with a dopamine D3 receptor ligand.

  本发明涉及式(I)的化合物，其中n为0、1或2；G为CH2或CHR3；R1为H、C1-C6烷基、C1-C6烷基取代的C3-C6环烷基、C1-C6羟基烷基、氟代C1-C6烷基、C3-C6环烷基、氟代C3-C6环烷基、C3-C6烯基、氟代C3-C6烯基、甲酰基、乙酰基或丙酰基；R2、R3和R4独立地为H、甲基、氟甲基、二氟甲基或三氟甲基；A为苯基、吡啶基、嘧啶基、吡嗪基、吡啶嗪基或噻吩基，可以被一个或多个卤素、甲基、甲氧基和CF3等取代基所取代；E为NR5或CH2，其中R5为H或C1-C3烷基；Ar为从苯基、一个5-或6-成员的杂环芳基基团中选择的循环基团，该杂环芳基基团的环成员包括1、2或3个从N、O和S选择的杂原子和与饱和或不饱和的5-或6-成员碳环或杂环芳基团融合的苯基环，其中所述杂环芳基团包括1、2或3个从N、O和S选择的杂原子和/或1、2或3个从NR8选择的含杂原子基团，其中R8为H、C1-C4烷基、氟代C1-C4烷基、C1-C4烷基羰基或氟代C1-C4烷基羰基，且所述循环基团Ar可以携带1、2或3个取代基Ra，其中变量Ra的含义如权利要求和说明书中所给出；以及其生理耐受的酸加合盐。本发明还涉及使用式I的化合物或其药学上可接受的盐制备用于治疗易于用多巴胺D3受体配体治疗的医疗疾病的药物组合物的用途。
• Pyrazinone derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US07148224B2

  公开（公告）日：2006-12-12

  The present invention relates to a compound of the general formula (I): [Ar1 is aryl fused to the adjacent pyrazinone ring at the 5th and 6th positions, etc., X is CO, etc., Y is CH, etc., Z is CH, etc., V is CH, etc., Wn is —(CH2)n— (n is zero to four), R1, is H or optionally substituted lower alkyl, etc., R2 is H, etc., R3 and R4 are the same or different and are each H, etc., R5 and R6 are the same or different and are each H, hydroxy, etc.] or a pharmaceutically acceptable salt or ester thereof; a pharmaceutical composition, an inhibitor of Cdk4 and/or Cdk6 or an anti-cancer agent, containing the same as an active ingredient; and a process for preparing them.

  本发明涉及通式（I）的化合物：[Ar1为芳基，与相邻的吡嗪酮环在第5和第6位置融合，等等，X为CO等，Y为CH等，Z为CH等，V为CH等，Wn为—（CH2）n—（n为零到四），R1为H或可选择的取代较低烷基等，R2为H等，R3和R4相同或不同，均为H等，R5和R6相同或不同，均为H，羟基等]或其药学上可接受的盐或酯；一种含有该化合物作为活性成分的制药组合物，Cdk4和/或Cdk6抑制剂或抗癌剂；以及其制备方法。